BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 1362916)

  • 1. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
    Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
    Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.
    Chong AS; Boussy IA; Graf LH; Scuderi P
    Cell Immunol; 1992 Oct; 144(1):69-79. PubMed ID: 1356634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples.
    Kutza J; Murasko DM
    Mech Ageing Dev; 1996 Sep; 90(3):209-22. PubMed ID: 8898314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.
    Wu R; Coleman N; Stanley M
    Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct characteristics of lymphokine-activated killer (LAK) cells derived from patients with B-cell chronic lymphocytic leukemia (B-CLL). A factor in B-CLL serum promotes natural killer cell-like LAK cell growth.
    Santiago-Schwarz F; Panagiotopoulos C; Sawitsky A; Rai KR
    Blood; 1990 Oct; 76(7):1355-60. PubMed ID: 2207313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
    Vu UE; Pavletic ZS; Wang X; Joshi SS
    Leuk Lymphoma; 2000 Nov; 39(5-6):573-82. PubMed ID: 11342340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
    Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
    Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
    Sone S; Utsugi T; Nii A; Ogura T
    J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
    Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L
    Blood; 1990 Oct; 76(7):1349-54. PubMed ID: 2207312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.
    Takahashi T; Ishikura H; Iwai K; Takahashi C; Kato H; Tanabe T; Yoshiki T
    Cancer Immunol Immunother; 1993; 36(2):76-82. PubMed ID: 8093857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.